42 results about "Viral Reverse Transcription" patented technology

An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV).

The present invention generally relates to the field of antiviral therapy. More specifically, the present invention relates to the inhibition of the tRNALys3-primed initiation of reverse transcription in viruses by APOBEC3G. The present invention further relates to a method of treating or preventing viral infections by inhibiting tRNALys3 annealing and / or priming on a viral genome thereby reducing viral replication. More particularly, the present invention relates to the use of APOBEC3G, fragments or derivatives thereof for treatment or prophylaxis of HIV-1 infection and related lentivirus infections.

The present invention relates to methods and compositions having trehalose and DNA polymerase for facilitating the rapid and efficient amplification of nucleic acid molecules and the detection and quantitation of RNA molecules, and for increasing the detection sensitivity and reliability through generation of secure cDNA molecules prior to gene-specific primer dependent amplification. The reagent mixture comprises a ready to use reagent solution, wherein the solution comprises: (a) trehalose in a concentration between about 5% and about 35%; (b) a viral reverse transcriptase; and (c) at least one DNA polymerases, in a buffer suitable for use in a reverse transcription reaction, wherein the buffer comprises a co-factor metal ion and nucleoside triphosphates.

The use of sesquiterpenes and, in particular sesquiterpene lactone endoperoxides, such as artemisinin and analogs thereof, for the treatment of hepatitis C virus infections. Artemisinin, analogs of artemsisnin and some crude Artemisia extracts were tested in vitro against DNA-viruses, retro-viruses and Flavivirida, (an important family of human and animal RNA pathogens). These compounds were also screened for anti-tumor activity. Strong activity of artemisinin was noticed against the bovine viral diarrhea virus (BVDV). As pestiviruses, such as BVDV, share many similarities with hepatitis C virus (HCV), we can conclude that endoperoxides in general and artemisinin more specificly have efficacy as treatments for hepatitis C viral infections.

The present invention provides novel compounds with activity against infectious viruses. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and / or related diseases. The present invention also relates generally to the accumulation or retention of therapeutic compounds inside cells. The invention is more particularly related to attaining high concentrations of active metabolite molecules in HIV infected cells. Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures.

An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.

The invention discloses a reverse transcription loop-mediated isothermal amplification test kit of a hog cholera virus and an application thereof. The test kit comprises an RT-LAMP primer, a 2*reaction buffer solution, an EM, a fluorescence visual detection reagent, ultrapure water and a hog cholera virus RNA template. The RT-LAMP primer comprises outer primers F3 and B3, inner primers FIP and BIP and a loop primer LF. The specific detection, the sensibility detection and the fluorescence visual detection prove that by adopting the RT-LAMP detecting method, the hog cholera virus can be specifically detected, the reaction can be real-time monitored, the copy number of the hog cholera virus can be quantitatively determined, the detecting result can be rapidly and accurately obtained, so that the simple, rapid and reliable detection of the hog cholera virus are facilitated.

The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology. The delivery is achieved by a simplified method which does not require cumbersome ex vivo techniques or additional matrix or scaffolding agents. Such viral and non-viral delivery vehicles of the present invention are derived from the following nonlimiting examples: adenoviruses, adeno-associated viruses, retroviruses, herpes simplex viruses, liposomes, and plasmids. The osteoinductive factors include, but are not limited to, growth factors, cytokines, growth factor inhibitors and cytokine inhibitors.

The invention belongs to the technical field of detection and diagnosis of aquatic animal pathogeny, and discloses a detection kit and detection method for siniperca chuatsi rhabdoviruses. The reverse transcription-polymerase chain reaction type rapid detection kit for the siniperca chuatsi rhabdoviruses is filled with a 5* reverse transcription buffer solution, reverse transcriptase, a random primer, 1.0 mL of 2*reaction mixed buffer solution, a preferably-designed sense primer, a preferably-designed reverse primer, Taq DNA polymerase, a positive control solution, a negative control solution and ddH2O. The novel reverse transcription-polymerase chain reaction type rapid detection kit and detection method for the siniperca chuatsi rhabdoviruses overcome shortcomings of an existing detection method for the siniperca chuatsi rhabdoviruses, are practicable when applied to clinical diagnosis of the siniperca chuatsi rhabdoviruses, have the advantages of rapidity, accuracy and specificity, meet requirements of the clinical diagnosis, and provide convenience for detection of the siniperca chuatsi rhabdoviruses.

The present invention relates to dideoxynucleoside analog compounds containing a dideoxy ribofuranosyl moiety that exhibit selective anti-viral activity coupled with substantially low toxicity toward the host cells. In particular, the compounds according to the present invention show potent inhibition of the replication of the human immunodeficiency virus (HIV), while remaining substantially inert toward host cell DNA. Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of retroviruses, particularly HIV. The compounds of the invention comprise a (2,3′-dideoxy-β-ribofuranosyl) ring coupled to a heterocyclic nucleobase that lacks an “O2 carbonyl”, that enables them to selectively react with and inhibit viral reverse transcriptase, while remaining substantially unreactive toward human DNA polymerases.

This invention pertains to a method for treating a human with human immunodeficiency virus infection which comprises administering to the human a therapeutically effective amount of a thymidine analog, which analog acts as an inhibitor of viral reverse transcriptase necessary for viral replication of human immunodeficiency virus, and a thymidylate synthase inhibitor, or pharmaceutically acceptable salts thereof.

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV).

The invention belongs to the technical field of aquaculture and in particular relates to a tilapia lake virus (TiLV) specificity RT-PCR detection kit and a detection method. The TiLV reverse transcription-polymerase chain reaction rapid detection kit comprises 5*reverse transcription buffer solution, reverse transcriptase, a random primer, 2*reaction mixed buffer solution, preferred designed upstream and downstream primers, Taq DNA polymerase, positive control solution, negative control solution and ddH2O. The invention overcomes the defects of an existing TiLV detection method and provides anovel reverse transcription-polymerase chain reaction rapid detection kit and a detection method; and the detection kit and the detection method are not only practicable in TiLV clinical diagnosis butalso have the advantages of speediness, accuracy, specificity and sensitivity, clinical diagnosis requirements are met, and convenient conditions are provided for TiLV detection.

A method for inspecting HBV, HCV, HIV, TP and RV simultaneously and rapidly is carried out by extracting virus inspection template, RNA virus reversed transcripting, PCR amplifying for five peccant microbe genes in the one same reactive system, inspecting by agarose gel electrophoresis method, positioning several peccant microbe gene sensitive target genes, designing multiple PCR nested or semi-nested primer and inspecting sensitively and rapidly. It can be used to inspect clinical human body or animal blood or tissue sample.

The present invention relates to compositions and methods having propylene glycol and DNA polymerase for facilitating the rapid and efficient amplification of nucleic acid molecules and the detection and quantitation of RNA molecules, and for increasing the detection sensitivity and reliability through generation of secure cDNA molecules prior to gene-specific primer dependent amplification. The reagent mixture comprises a ready to use reagent solution, wherein the solution comprises: (a) propylene glycol in a concentration between about 20% and about 50%; (b) a viral reverse transcriptase; and (c) at least one DNA polymerases, in a buffer suitable for use in a reverse transcription reaction, wherein the buffer comprises a co-factor metal ion and nucleoside triphosphates.

The invention discloses a visual reverse transcription loop-mediated isothermal amplification (RT-LAMP) kit for the porcine kobuvirus and application thereof. The kit comprises an RT-LAMP primer, 2*reaction buffer, effective microorganisms (EM), a fluorescent visual detection reagent, ultrapure water and a porcine kobuvirus ribonucleic acid (RNA) template, wherein the RT-LAMP primer comprises outer primers F3 and B3, inner primers FIP and BIP and loop primers LF and LB. The kit is applied to detecting the pathological tissues of the porcine kobuvirus and virus-containing excrement. Specific detection and sensitivity detection verify that the RT-LAMP kit provided by the invention can monitor reaction in real time and quantitatively detect the copy number of the porcine kobuvirus, quickly and accurately obtain the detection results and bring convenience for simply, conveniently, quickly and reliably detecting the porcine kobuvirus.

The invention discloses a hepatitis B virus multi-locus genotypic resistance mutation detection method. A single tube nest type polymerase gene amplification method for detecting reverse transcriptase full gene sequence of virus includes that nest type PCR amplification is carried out in a single tube for twice, products of a first group PCR reaction are all used as templates of a second group PCR reaction by adjusting concentration of internal and external primers, and finally nest type PCR reaction is completed in the same single tube. The invention ensures specificity and economy of detection while obviously improving detection sensibility and has the detection range over a hundred million difference viral load.

A method of producing a Rous Sarcoma Virus reverse transcriptase (RSV RT) by expressing one orniore nucleic acid sequences encoding one or more subunits of RSV RT in a eukaryotic host cell and culturing the host cell under conditions sufficient to produce the recombinant RSV RT. The resulting RSV RT has a specific activity of between about 30,000 and 150,000 units per milligram and is suitable for methods including RT-polyinerase chain reaction (RT-PCR).

The present invention relates to novel phosponate nucleosides, more specifically to novel phosponalkoxy substituted nucleosides. The invention further relates to compounds having HIV (Human Immunodeficiency Virus) replication inhibiting properties and to compounds having antiviral activities with respect to other viruses. The invention also relates to methods for preparation of all such compounds and pharmaceutical compositions comprising them. The invention further relates to the use of said compounds as a medicine and in the manufacture of a medicament useful for the treatment of subjects suffering from HIV infection, as well as for treatment of other viral, retroviral or lentiviral infections and to the treatment of animals suffering from FIV, viral, retroviral or lentiviral infections.

The invention provides a grass carp reovirus (GCRV) reverse transcription polymerase chain reaction nucleic acid detection method, comprising the following steps: directly extracting the total RNA in the samples to be detected by adopting a RNA adsorption column centrifugal method; detecting the s10 gene segment of the structural protein VP 7 with the code of GCRV of the outer capsid by reverse transcription chain reaction. The sample to be detected comprises normal cells, cells infected by virus, normal fish tissues and tissues of infected fish. The detection method has the advantages that the total RNA can be extracted from the samples to be detected by the column centrifugal method and RT-PCR amplification can be carried out by only needing a small amount of tissue of the samples to be detected; the minimum detection sensitivity is 10<-6>ng, and the required time is only 4-5 hours; the detection method is simple and reliable, high in sensitivity and strong in specificity; and the result is prospective to be used for GCRV clinical quick diagnosis and entry-exit customs quarantine of fish fry.

The invention belongs to the technical field of detection and diagnosis of aquatic animal pathogeny, and discloses a detection kit and detection method for siniperca chuatsi rhabdoviruses. The reverse transcription-polymerase chain reaction type rapid detection kit for the siniperca chuatsi rhabdoviruses is filled with a 5* reverse transcription buffer solution, reverse transcriptase, a random primer, 1.0 mL of 2*reaction mixed buffer solution, a preferably-designed sense primer, a preferably-designed reverse primer, Taq DNA polymerase, a positive control solution, a negative control solution and ddH2O. The novel reverse transcription-polymerase chain reaction type rapid detection kit and detection method for the siniperca chuatsi rhabdoviruses overcome shortcomings of an existing detection method for the siniperca chuatsi rhabdoviruses, are practicable when applied to clinical diagnosis of the siniperca chuatsi rhabdoviruses, have the advantages of rapidity, accuracy and specificity, meet requirements of the clinical diagnosis, and provide convenience for detection of the siniperca chuatsi rhabdoviruses.

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV).

A method for confirming a 3.-terminus sequence of a virus RNA (Ribonucleic Acid) molecule comprises the following steps of: extraction of virus RNA, tail transfer reaction of the virus RNA, purification of tailing virus RNA, reverse transcription reaction of the tailing virus RNA, and polymerase chain reaction amplification of a product of the virus reverse transcription reaction. According to the invention, after tailing is performed on the virus RNA by the tail transfer reaction, the 3.-terminus sequence of the virus RNA molecule can be accurately confirmed by the reverse transcription reaction, thus the method is convenient and quick. As an Oligo dT primer or a modified Oligo dT primer is utilized to perform the reverse transcription reaction, the process of designing and compounding a specific primer according to a specific virus RNA molecule is eliminated, so that the period of an experiment is simplified greatly, and the experiment cost is saved. Simultaneously, the method can be applied to confirming other 3.-terminus sequences of the RNA molecule the 3.-terminus of which does not have a PolyA tail structure.

The present invention provides novel compounds with activity against infectious viruses. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and / or related diseases. The present invention also relates generally to the accumulation or retention of therapeutic compounds inside cells. The invention is more particularly related to attaining high concentrations of active metabolite molecules in HIV infected cells. Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures.

The invention relates to a general expression framework of artificial circular RNA targeting to inhibit miRNA-34a, and an expression method and an application thereof. The general expression frameworkconsists of three parts: an upstream sequence, an intermediate sequence and a downstream sequence. The general expression framework of the artificial circular RNA targeting to inhibit miRNA-34a can be mediated in cells by plasmids or viral tools to express artificial circular RNA molecules targeting to inhibit miRNA-34a, and has the ability to inhibit the biological function of miRNA-34a-5p in cells. The invention also relates to the general expression framework and the application of eukaryotic expression plasmids, lentiviruses, adenoviruses, adeno-associated viruses and retroviruses carrying the expression framework in preparation of drugs for obesity, fatty liver, hyperlipidemia and diabetes.

The invention provides a technology for intervening and blocking reverse transcription transposition of a reverse transcription organism based on CRISPR-Cas13a. The invention discloses a technology for intervening and blocking reverse transcription transposition of the reverse transcription organism based on CRISPR-Cas13a, a system for blocking reverse transcription transposition of the reverse transcription organism in eukaryotic cells and application of the system. In the invention, research and demonstration are carried out on the basis of the model system of the retrovirus Tf1. According to the technical scheme, Cas13a is used for inhibiting reverse transcription transposition for the first time, and the reverse transcription transposition blocking efficiency of Cas13a is ideal.